SCHEDULE 13G: BlackRock Discloses 5.0% Stake in Tango Therapeutics

BlackRock, Inc. has filed a Schedule 13G, reporting beneficial ownership of 5.0% of Tango Therapeutics, Inc.'s common stock as of June 30, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 5,457,030 shares of Tango Therapeutics, Inc. common stock.
• This stake represents 5.0% of the total outstanding common shares of Tango Therapeutics, Inc.
• BlackRock holds sole voting power over 5,323,498 shares and sole dispositive power over 5,457,030 shares.
• The filing was made under Rule 13d-1(b), indicating BlackRock is a parent holding company or control person.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of a significant passive ownership stake by a major institutional investor, which can be viewed as a neutral to slightly positive signal of confidence in the company, but it does not contain performance or operational updates.

Positives

• BlackRock, a major institutional investor, holds a significant 5.0% stake in Tango Therapeutics, which can be viewed as a vote of confidence in the company.
• The filing indicates that BlackRock's acquisition of shares was in the ordinary course of business and not for the purpose of influencing control, suggesting a passive investment strategy.

Future Outlook

The Schedule 13G filing does not provide any forward-looking statements or guidance regarding Tango Therapeutics, Inc.'s future operations or financial performance. It solely reports BlackRock, Inc.'s beneficial ownership stake.

Management Comments

• To the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

Schedule 13G filings are standard disclosures by institutional investors, such as BlackRock, when they acquire beneficial ownership of more than 5% of a company's voting class of securities. These filings indicate a passive investment intent, differentiating them from Schedule 13D filings, which suggest an intent to influence or control the issuer. BlackRock's significant stake in Tango Therapeutics reflects its ongoing portfolio management activities across various public companies.

Stakeholder Impact

• Shareholders: BlackRock's 5.0% stake may be perceived as a positive signal of institutional confidence, potentially influencing investor sentiment.

Key Dates

Keywords

Tango Therapeutics, BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Equity Stake